Cargando…
Technical Review of Clinical Outcomes Assessments Across the Continuum of Alzheimer's Disease
INTRODUCTION: Insight into the relationship between concepts that matter to the people affected by Alzheimer’s disease (AD) and the clinical outcome assessments (COAs) commonly used in AD clinical studies is limited. Phases 1 and 2 of the What Matters Most (WMM) study series identified and quantitat...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10043075/ https://www.ncbi.nlm.nih.gov/pubmed/36790638 http://dx.doi.org/10.1007/s40120-023-00443-2 |
_version_ | 1784913067137564672 |
---|---|
author | DiBenedetti, Dana B. Menne, Heather Paulsen, Russ Krasa, Holly B. Vradenburg, George Comer, Meryl Callahan, Leigh F. Winfield, John Potashman, Michele Heithoff, Kim Hartry, Ann Oberdhan, Dorothee Wilson, Hilary Hoffman, Deborah L. Wieberg, Dan Kremer, Ian N. Taylor, Geraldine A. Taylor, James M. Lappin, Debra Martin, Allison D. Hauber, Brett Romano, Carla |
author_facet | DiBenedetti, Dana B. Menne, Heather Paulsen, Russ Krasa, Holly B. Vradenburg, George Comer, Meryl Callahan, Leigh F. Winfield, John Potashman, Michele Heithoff, Kim Hartry, Ann Oberdhan, Dorothee Wilson, Hilary Hoffman, Deborah L. Wieberg, Dan Kremer, Ian N. Taylor, Geraldine A. Taylor, James M. Lappin, Debra Martin, Allison D. Hauber, Brett Romano, Carla |
author_sort | DiBenedetti, Dana B. |
collection | PubMed |
description | INTRODUCTION: Insight into the relationship between concepts that matter to the people affected by Alzheimer’s disease (AD) and the clinical outcome assessments (COAs) commonly used in AD clinical studies is limited. Phases 1 and 2 of the What Matters Most (WMM) study series identified and quantitatively confirmed 42 treatment-related outcomes that are important to people affected by AD. METHODS: We compared WMM concepts rated as “very important” or higher to items included in COAs used commonly in AD studies. RESULTS: Twenty COAs designed to assess signs, symptoms, and impacts across the spectrum of AD were selected for review. Among these 20 COAs, only 5 reflected 12 or more WMM concepts [Integrated Alzheimer's Disease Rating Scale (iADRS), Alzheimer's Disease Cooperative Study–Activities of Daily Living Inventory (ADCS-ADL), Alzheimer's Disease Cooperative Study–Activities of Daily Living Inventory–Mild Cognitive Impairment (ADCS-ADL-MCI), Alzheimer's Disease Composite Scores (ADCOMS), and Clinical Dementia Rating; Clinical Dementia Rating-Sum of Boxes (CDR/CDR-SB)]. Multiple symptoms and impacts of AD identified as important and meaningful in the WMM studies map only indirectly at best to 7 of the 20 most widely used COAs. CONCLUSION: While many frequently used COAs in AD capture some concepts identified as important to AD populations and their care partners, overlap between any single measure and the concepts that matter to people affected by AD is limited. The highest singly matched COA reflects fewer than half (45%) of WMM concepts. Use of multiple COAs expands coverage of meaningful concepts. Future research should explore the content validity of AD COAs planned for AD trials based on further confirmation of the ecological validity of the WMM items. This research should inform development and use of core outcome sets that capture WMM items and selection or development of new companion tools to fully demonstrate clinically meaningful outcomes spanning WMM. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40120-023-00443-2. |
format | Online Article Text |
id | pubmed-10043075 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-100430752023-03-29 Technical Review of Clinical Outcomes Assessments Across the Continuum of Alzheimer's Disease DiBenedetti, Dana B. Menne, Heather Paulsen, Russ Krasa, Holly B. Vradenburg, George Comer, Meryl Callahan, Leigh F. Winfield, John Potashman, Michele Heithoff, Kim Hartry, Ann Oberdhan, Dorothee Wilson, Hilary Hoffman, Deborah L. Wieberg, Dan Kremer, Ian N. Taylor, Geraldine A. Taylor, James M. Lappin, Debra Martin, Allison D. Hauber, Brett Romano, Carla Neurol Ther Original Research INTRODUCTION: Insight into the relationship between concepts that matter to the people affected by Alzheimer’s disease (AD) and the clinical outcome assessments (COAs) commonly used in AD clinical studies is limited. Phases 1 and 2 of the What Matters Most (WMM) study series identified and quantitatively confirmed 42 treatment-related outcomes that are important to people affected by AD. METHODS: We compared WMM concepts rated as “very important” or higher to items included in COAs used commonly in AD studies. RESULTS: Twenty COAs designed to assess signs, symptoms, and impacts across the spectrum of AD were selected for review. Among these 20 COAs, only 5 reflected 12 or more WMM concepts [Integrated Alzheimer's Disease Rating Scale (iADRS), Alzheimer's Disease Cooperative Study–Activities of Daily Living Inventory (ADCS-ADL), Alzheimer's Disease Cooperative Study–Activities of Daily Living Inventory–Mild Cognitive Impairment (ADCS-ADL-MCI), Alzheimer's Disease Composite Scores (ADCOMS), and Clinical Dementia Rating; Clinical Dementia Rating-Sum of Boxes (CDR/CDR-SB)]. Multiple symptoms and impacts of AD identified as important and meaningful in the WMM studies map only indirectly at best to 7 of the 20 most widely used COAs. CONCLUSION: While many frequently used COAs in AD capture some concepts identified as important to AD populations and their care partners, overlap between any single measure and the concepts that matter to people affected by AD is limited. The highest singly matched COA reflects fewer than half (45%) of WMM concepts. Use of multiple COAs expands coverage of meaningful concepts. Future research should explore the content validity of AD COAs planned for AD trials based on further confirmation of the ecological validity of the WMM items. This research should inform development and use of core outcome sets that capture WMM items and selection or development of new companion tools to fully demonstrate clinically meaningful outcomes spanning WMM. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40120-023-00443-2. Springer Healthcare 2023-02-15 /pmc/articles/PMC10043075/ /pubmed/36790638 http://dx.doi.org/10.1007/s40120-023-00443-2 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Original Research DiBenedetti, Dana B. Menne, Heather Paulsen, Russ Krasa, Holly B. Vradenburg, George Comer, Meryl Callahan, Leigh F. Winfield, John Potashman, Michele Heithoff, Kim Hartry, Ann Oberdhan, Dorothee Wilson, Hilary Hoffman, Deborah L. Wieberg, Dan Kremer, Ian N. Taylor, Geraldine A. Taylor, James M. Lappin, Debra Martin, Allison D. Hauber, Brett Romano, Carla Technical Review of Clinical Outcomes Assessments Across the Continuum of Alzheimer's Disease |
title | Technical Review of Clinical Outcomes Assessments Across the Continuum of Alzheimer's Disease |
title_full | Technical Review of Clinical Outcomes Assessments Across the Continuum of Alzheimer's Disease |
title_fullStr | Technical Review of Clinical Outcomes Assessments Across the Continuum of Alzheimer's Disease |
title_full_unstemmed | Technical Review of Clinical Outcomes Assessments Across the Continuum of Alzheimer's Disease |
title_short | Technical Review of Clinical Outcomes Assessments Across the Continuum of Alzheimer's Disease |
title_sort | technical review of clinical outcomes assessments across the continuum of alzheimer's disease |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10043075/ https://www.ncbi.nlm.nih.gov/pubmed/36790638 http://dx.doi.org/10.1007/s40120-023-00443-2 |
work_keys_str_mv | AT dibenedettidanab technicalreviewofclinicaloutcomesassessmentsacrossthecontinuumofalzheimersdisease AT menneheather technicalreviewofclinicaloutcomesassessmentsacrossthecontinuumofalzheimersdisease AT paulsenruss technicalreviewofclinicaloutcomesassessmentsacrossthecontinuumofalzheimersdisease AT krasahollyb technicalreviewofclinicaloutcomesassessmentsacrossthecontinuumofalzheimersdisease AT vradenburggeorge technicalreviewofclinicaloutcomesassessmentsacrossthecontinuumofalzheimersdisease AT comermeryl technicalreviewofclinicaloutcomesassessmentsacrossthecontinuumofalzheimersdisease AT callahanleighf technicalreviewofclinicaloutcomesassessmentsacrossthecontinuumofalzheimersdisease AT winfieldjohn technicalreviewofclinicaloutcomesassessmentsacrossthecontinuumofalzheimersdisease AT potashmanmichele technicalreviewofclinicaloutcomesassessmentsacrossthecontinuumofalzheimersdisease AT heithoffkim technicalreviewofclinicaloutcomesassessmentsacrossthecontinuumofalzheimersdisease AT hartryann technicalreviewofclinicaloutcomesassessmentsacrossthecontinuumofalzheimersdisease AT oberdhandorothee technicalreviewofclinicaloutcomesassessmentsacrossthecontinuumofalzheimersdisease AT wilsonhilary technicalreviewofclinicaloutcomesassessmentsacrossthecontinuumofalzheimersdisease AT hoffmandeborahl technicalreviewofclinicaloutcomesassessmentsacrossthecontinuumofalzheimersdisease AT wiebergdan technicalreviewofclinicaloutcomesassessmentsacrossthecontinuumofalzheimersdisease AT kremeriann technicalreviewofclinicaloutcomesassessmentsacrossthecontinuumofalzheimersdisease AT taylorgeraldinea technicalreviewofclinicaloutcomesassessmentsacrossthecontinuumofalzheimersdisease AT taylorjamesm technicalreviewofclinicaloutcomesassessmentsacrossthecontinuumofalzheimersdisease AT lappindebra technicalreviewofclinicaloutcomesassessmentsacrossthecontinuumofalzheimersdisease AT martinallisond technicalreviewofclinicaloutcomesassessmentsacrossthecontinuumofalzheimersdisease AT hauberbrett technicalreviewofclinicaloutcomesassessmentsacrossthecontinuumofalzheimersdisease AT romanocarla technicalreviewofclinicaloutcomesassessmentsacrossthecontinuumofalzheimersdisease |